Every Form 4 that Ironwood Pharmaceuticals, Inc. (IRWD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IRWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRWD filings page.
IRONWOOD PHARMACEUTICALS INC (symbol: IRWD) is the issuer of record for a Form 4 filing submitted to the SEC. DENNER ALEXANDER J reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC (IRWD) reported that director Alexander J. Denner received an equity grant of 3,694 shares of Class A Common Stock on September 15, 2026. The shares were issued at no cash cost under the company’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, increasing his direct holdings to 327,549 shares. No Rule 10b5-1 trading plan is reported for this award.
Silber Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Ironwood Pharmaceuticals Inc granted its SVP, CMO and Head of Research & Drug Development, Jeffrey Silber, a new-hire restricted stock unit award covering 137,036 shares of Class A Common Stock. The award vests 25% of the shares on each approximate anniversary of the grant, resulting in direct ownership of 137,036 shares.
Ironwood Pharmaceuticals’ principal financial and accounting officer Ronald Silver sold 127,890 shares of Class A common stock in an open-market transaction. The sale was executed under a pre-arranged Rule 10b5-1 trading plan at a weighted average price of $4.52 per share, with individual trade prices ranging from $4.50 to $4.57.
After this transaction, Silver directly holds 313,680 Ironwood shares, indicating he retains a significant equity stake even after the planned sale.
Shepard Jay reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC director Jay Shepard received a grant of 63,481 shares of Class A common stock as equity compensation. The restricted stock was granted at no cash cost to him under the Second Amended and Restated Non-employee Director Compensation Policy.
According to the grant terms, these restricted shares vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year. Following this award, Shepard directly holds a total of 235,036 shares of Ironwood Class A common stock.
Kessler Marla L reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC director Marla L. Kessler received a grant of 63,481 shares of Class A Common Stock as restricted stock. The award was granted under the company’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
The restricted stock vests in full on the date immediately preceding the annual meeting of stockholders for the next calendar year. Following this grant, Kessler directly holds 229,364 shares of Class A Common Stock, reflecting routine equity-based director compensation rather than an open-market purchase or sale.
Currie Mark G reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC director Mark G. Currie received a grant of 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost to him as part of director compensation.
According to the company’s non-employee director compensation policy, this restricted stock vests in full on the date immediately before the next year’s annual meeting of stockholders. After this award, Currie directly holds 676,900 shares of Ironwood common stock.
Duane Jon R reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC director Jon R. Duane received a grant of 63,481 shares of Class A Common Stock as equity compensation. The award was made at a price of $0.00 per share under the company’s Second Amended and Restated Non-employee Director Compensation Policy.
The restricted stock will vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year. Following this grant, Duane directly holds a total of 253,820 shares of Ironwood Pharmaceuticals common stock. This filing reflects a routine director equity award rather than an open-market purchase or sale.
Ironwood Pharmaceuticals director Alexander J. Denner reported stock awards of Class A Common Stock, received as non-cash compensation. On June 16, 2026, he acquired 63,481 shares at a price of $0.00 per share, increasing his direct holdings to 323,855 shares.
On June 15, 2026, he was also granted 4,065 shares at $0.00 per share, with 260,374 shares held directly after that grant. The footnotes state these restricted shares were issued under Ironwood’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, and will vest in full on the date immediately preceding the next year’s annual meeting of stockholders.
IRONWOOD PHARMACEUTICALS INC director Julie McHugh reported both a sale and a share grant of Class A Common Stock. She sold 21,571 shares at a weighted average price of $3.73 per share in open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan. She also received a grant of 63,481 restricted shares at no cost under the company’s non-employee director compensation policy. These restricted shares vest in full on the date immediately preceding the next calendar year’s annual meeting of stockholders. After these transactions, she directly holds 250,749 shares.
Moukheibir Catherine reported acquisition or exercise transactions in this Form 4 filing.
Ironwood Pharmaceuticals director Catherine Moukheibir received an equity award of 63,481 shares of Class A common stock as compensation. The shares were granted at no cash cost to her and are structured as restricted stock under the company’s Second Amended and Restated Non-employee Director Compensation Policy.
These restricted shares will vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year, meaning she must remain in service through that date to receive them. After this grant, Moukheibir directly holds a total of 181,425 shares of Ironwood Class A common stock.
Silver Ronald reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC executive Ronald Silver, who serves as PFO & PAO, received a grant of 25,000 shares of Common Stock in the form of restricted stock units. The award was granted at a price of $0.00 per share as equity compensation.
The restricted stock unit award vests in two equal installments, with 50% of the underlying Class A Common Stock vesting on each approximate anniversary of the grant date. After this award, Silver directly holds 441,570 shares of the company’s Common Stock.
IRONWOOD PHARMACEUTICALS INC director-related entities reported major share sales alongside a small equity grant. Investment vehicles advised by Sarissa Capital Management LP sold a total of 6,730,800 shares of Class A Common Stock on March 17, 2026 in open-market transactions at prices between $3.05 and $3.31 per share, leaving 9,188,635 shares held indirectly. Separately, Dr. Alexander J. Denner received a grant of 4,451 shares on March 13, 2026 under the company’s non-employee director compensation policy, bringing his directly held shares to 256,309. Footnotes state Sarissa Capital and its funds directly hold the sold and remaining indirect shares, with each party, including Dr. Denner, disclaiming beneficial ownership beyond their pecuniary interest.
Ironwood Pharmaceuticals Chief Legal Officer John Minardo received an equity grant of 136,612 shares of Class A Common Stock as a stock award. The shares were acquired at no cash cost to him as a grant or award, rather than an open-market purchase.
The award was granted in the form of restricted stock units as an annual performance award and will vest in four equal installments, with 25% of the underlying shares vesting on each approximate anniversary of the grant date. Following this grant, Minardo directly holds a total of 500,498 shares of Class A Common Stock.
Ironwood Pharmaceuticals reported that Chief Financial Officer Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. The award is structured as restricted stock units granted as an annual performance award.
The award vests in four equal installments, with 25% of the shares vesting on each approximate anniversary of the grant date. Following this grant, Martini directly holds 297,213 shares of Class A Common Stock. This is a compensation-related acquisition, not an open-market purchase or sale.
Gaskins Tammi L reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC reported that Chief Commercial Officer Tammi L. Gaskins received an equity grant of 136,612 shares of Class A Common Stock in the form of restricted stock units. These units were granted at no cash cost and represent a compensation award rather than an open-market purchase.
The award, described as an annual performance grant, vests in four equal installments of 25% on each approximate anniversary of the grant date, tying value to continued service and performance over time. Following this grant, Gaskins’ direct holdings increased to 350,350 shares of Class A Common Stock.
Shetzline Michael reported acquisition or exercise transactions in this Form 4 filing.
Ironwood Pharmaceuticals reported that SVP and Chief Medical Officer Michael Shetzline received a grant of 136,612 shares of Class A Common Stock as an annual performance-related restricted stock unit award. The grant has no purchase price and will vest in 25% increments on each approximate anniversary of the grant, leaving him with 658,037 shares directly owned after the award.
Silver Ronald reported acquisition or exercise transactions in this Form 4 filing.
Ironwood Pharmaceuticals’ principal accounting officer Ronald Silver received a stock-based compensation grant. He was awarded 163,934 shares of Class A Common Stock as restricted stock units, with no cash paid per share. The award vests in four equal annual installments. Following this grant, he directly holds 416,570 shares.
MCCOURT Thomas A reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC reported that Chief Executive Officer Thomas A. McCourt received a grant of 409,836 shares of Class A Common Stock as a restricted stock unit award. This annual performance award vests in three equal installments of 33.33% on each approximate anniversary of the grant.
Following this award, McCourt directly holds 1,898,838 shares of Class A Common Stock. The grant is compensation-related and was recorded at no cash purchase price per share.
Ironwood Pharmaceuticals Chief Legal Officer John Minardo reported automatic sales of 36,492 shares of Class A common stock to cover tax withholding on vested restricted stock units. These open-market transactions occurred on February 23 and 24 at weighted average prices of $3.81 and $3.66 per share, within disclosed intraday price ranges.
After these sell-to-cover trades, Minardo directly held 363,886 Ironwood shares. The filing notes that the sales were executed automatically to satisfy tax obligations and did not represent discretionary trading decisions.
Ironwood Pharmaceuticals SVP and CMO Michael Shetzline reported automatic share sales to cover taxes on vesting restricted stock units. On Class A Common Stock and Common Stock, he sold a total of 32,582 shares in open-market transactions at weighted average prices around $3.81 and $3.66 per share. These sales were executed solely to satisfy tax withholding obligations and were not discretionary trades, and he continued to hold 521,425 shares afterward.
IRONWOOD PHARMACEUTICALS INC Chief Commercial Officer Tammi L. Gaskins reported automatic sales of Class A common stock to cover taxes on vesting restricted stock units. She sold 10,287 shares on February 23 at a weighted average price of $3.81 and 11,239 shares on February 24 at a weighted average price of $3.66, in open-market transactions. The filing states these were mandatory “sell to cover” transactions for tax withholding and not discretionary trades. After these sales, she held 213,738 shares of Ironwood common stock directly.
Ironwood Pharmaceuticals Chief Executive Officer Thomas A. McCourt reported automatic sales of Class A Common Stock to cover tax withholding from vested restricted stock units. On February 23 and 24, 2026, a total of 198,283 shares were sold in open-market transactions classified as non-derivative sales.
The filing notes these were sell-to-cover transactions executed automatically to satisfy tax obligations and did not represent discretionary trades by McCourt. Weighted average sale prices were reported, with shares on one day sold between $3.70 and $4.05 and on the other between $3.60 and $3.73. Following the February 24 sale, he directly held 1,489,002 shares. A footnote also records his acquisition of 4 shares under the company’s employee stock purchase plan on December 31, 2025.
IRONWOOD PHARMACEUTICALS INC Chief Financial Officer Gregory S. Martini reported automatic stock sales to cover taxes tied to restricted stock vesting. On February 23, he sold 10,487 shares of Class A common stock at a weighted-average price of $3.81 per share in open-market transactions within a $3.70–$4.05 range. On February 24, he sold an additional 11,457 shares at a weighted-average price of $3.66 per share within a $3.60–$3.73 range. The filing states these sales were executed automatically solely to satisfy tax withholding obligations and were not discretionary trades. After these transactions, Martini directly owned 160,601 shares of Ironwood Class A common stock.
IRONWOOD PHARMACEUTICALS INC principal accounting officer Ronald Silver reported automatic sales of 24,173 Class A common shares to cover tax withholding obligations from vesting restricted stock units. The transactions involved 11,552 shares on February 23, 2026 at a weighted average price of $3.81 and 12,621 shares on February 24, 2026 at a weighted average price of $3.66. The prices reflect multiple trades within disclosed ranges. After these tax-related, non-discretionary sales, Silver directly held 252,636 shares of Ironwood Pharmaceuticals common stock.
Ironwood Pharmaceuticals officer Ronald Silver reported a planned stock sale. On January 5, 2026, he sold 35,416 shares of Ironwood Class A Common Stock at $4.60 per share in a transaction coded as a sale. The filing states this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Silver, which is designed to allow insiders to sell shares according to a set schedule. After this transaction, he beneficially owned 276,809 shares of Ironwood stock, held directly. A footnote explains that the 35,416 shares sold had been acquired under Ironwood’s employee stock purchase plan on December 31, 2025.
Ironwood Pharmaceuticals insider activity: A reporting person associated with Ironwood Pharmaceuticals received an award of 4,178 shares of Class A common stock on 12/15/2025 at a price of $0 per share. The filing states this grant was issued under the company’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
After this transaction, the reporting person directly beneficially owns 251,858 Class A shares and indirectly beneficially owns 15,919,435 Class A shares through Sarissa Capital Management LP and related funds, reflecting both personal and fund-related positions in IRONWOOD PHARMACEUTICALS INC (IRWD).
Ironwood Pharmaceuticals Inc. (IRWD) reported an insider transaction by its Chief Commercial Officer. On 11/17/2025, the officer sold 6,016 shares of Class A common stock at $3.32 per share. According to the disclosure, this sale was made automatically to cover tax withholding obligations arising from the vesting of restricted stock units and was not a discretionary trade. After this transaction, the officer beneficially owned 235,264 shares of Ironwood common stock.